Bay Navigator

Neurology
Stroke Care

Stroke Prevention

  1. Primary Stroke Prevention

    • Address risk factors:
      • BP
      • Glucose
      • Cholesterol
      • Smoking history
      • Obesity
      • Exercise
      • Excess alcohol
      • Atrial Fibrillation
    • Heart Foundation "Know your numbers"
    • Consider using the Global Vascular Risk assessment tool
  2. Prevention Patient Education Resources and Opportunities

    • A plethora of stroke information leaflets/booklets/fridge magnets are available through the Stroke Foundation - some of these can be printed off and others ordered for free.
    • It is important that all ages are able to recognise the symptoms of Stroke i.e. be aware of FAST, as it will most likely be a family member rather than the patient themselves who pick up the symptoms.   
    • Why not:
      1. Consider giving information leaflets out when giving 65-year-old tetanus boosters
      2. Give a free fridge magnet with each Flu vaccination next year
      3. Give out information whenever a Driver's medical is done
    • Stroke Foundation Free Resources

Assessment

  1. FAST+ve Presentation at GP, Rest Home or Community

    • Typical features include
      • Weakness and paralysis – may be confined to face, arm or leg only.
      • Problems with speech and comprehension or slurred speech.
      • Visual disturbances.
      • Disorders or perception disorder of balance, co-ordination.
      • Acute problems with swallowing.
      • Acute presentations restricted to isolated dizziness/vertigo or isolated delirium (not aphasia) or isolated loss of consciousness should not be managed as stroke, but may still need urgent attention.
    • FAST (F-A-S-T): Use the Face, Arm, Speech, Time Test to screen for diagnosis of stroke, but note some patients with stroke will be FAST negative. Examples include hemianopias, quadrantanopia or diplopia or ataxic limbs. (Posterior Circulation Stroke).
      • F– new onset facial weakness:
        • Ask patient to smile or show their teeth.
        • The FAST test is +ve if there is new facial asymmetry.
      • A– new onset arm weakness:
        • Raise the patients arms to 90 degrees if they are sitting or 45 degrees if they are lying.
        • Ask the patient to maintain the position when you let go.
        • The FAST test is +ve if, when you let go, one arm falls or drifts.
      • S– speech problems:
        • Assess the patient’s speech and determine if it is slurred or the person has difficulty finding the name for commonplace objects.
        • If they have difficulty seeing, place the object in their hands.
        • If they have a companion, check whether this is a new problem.
        • The FAST test is +ve if there is a new unexplained speech problem.
      • T– ‘time in brain’. Urgent treatment in the hospital to reverse symptoms may be possible – do not delay.
    • The ROSIER (Risk of Stroke in the Emergency Room) assessment scale. This scale is used in ED as an assessment tool, when symptoms are less clear. This form can be used in General Practice to assist diagnosis. The Rosier has a 93% sensitivity, a 83% specificity, 90% positive predictive value, and a 88% negative predictive value. Ref Lancet Neurol. 2005 Nov: 4 (11) 691-3.
    • The FAST screening test looks for signs of stroke in the carotid (anterior) circulation. Around 80-85% of strokes will be FAST +ve. Remember that posterior circulation strokes also need to be admitted to hospital.
    • Anterior (carotid) circulation  Posterior (vertebrobasilar) circulation
      • Cortical dysfunction (ie dysphasia, sensory or visual inattention, hemianopia)
      • Monocular blindness
      • Unilateral weakness
      • Unilateral sensory disturbance
      • Dysarthria*
      • Neuromuscular dysphagia*
      • Cranial nerve palsy
      • Ataxia/inco-ordination
      • Diplopia
      • Isolated homonymous hemianopia
      • Bilateral visual loss
      • Unilateral/bilateral weakness
      • Unilateral/bilateral sensory disturbance
      • Dysarthria*
      • Neuromuscular dysphagia*

      *Less likely to be TIA/stroke if symptoms in isolation.

General Management

  1. If symptoms have resolved, refer to Bay Navigator TIA
  2. Exclude Hypoglycaemia
  3. Transfer immediately to hospital

Management for Strokes <4 hours from the symptom onset

  1. Thrombolysis window, if <4 hours from the symptom onset

    • Strokes may be reversible if thrombolysis is given within the 4.5-hour time window. Thrombolysis is time critical: every minute of delay results in a poorer outcome.
    • Patient Information document on 
      Alteplase (rt-PA) in Acute Ischemic Stroke

      You (or your whanau-relative) are being considered for treatment with Alteplase, a recombinant tissue plasminogen activator (rt-PA). In order to decide whether you wish to receive therapy, you should understand enough about the possible risks and benefits to make an informed decision. You will have about 15 minutes to consider this. An interpreter will be provided if at all possible within the time constraints of treatment.

      Introduction

      Most stokes are caused by loss of blood supply to a part of the brain. This is usually due to a clot in a blood vessel supplying the affected part of the brain. Dissolving the clot with Alteplase can restore the blood flow to the affected brain and may reduce the amount of permanent brain damage. Alteplase is only given after your consent and following discussion of the potential benefits and risks of treatment. Alteplase is given by injection into a vein over 1 hour.

      What are the possible benefits of receiving Alteplase?

      Alteplase has been shown to reduce the risk of disability in stroke patients treated up to 4.5 hours after the onset of stroke symptoms. The earlier Alteplase treatment can be given, the greater the chance of improved outcome. This is the reason for the short time in which to make a decision. This time-dependent effect of treatment can be demonstrated with the ‘number’s needed to treat’ to see significant benefit. One patient treated with Alteplase has a significantly improved outcome for every:

      • Three patients treated within 1.5 hours
      • Eight patients treated within 3 hours, 1 has a significantly improved outcome
      • Fourteen patients treated between 3-4.5 hours, 1 has a significantly improved outcome


      These figures take into account the increased risk of bleeding with Alteplase.

      What are the possible risks from receiving Alteplase?

      Treatment with Alteplase significantly reduces the risk of death or disability following stroke. There is an increased risk of bleeding into the brain but this risk is outweighed by the benefits of treatment.

      Alteplase is generally well tolerated but you (or your whanau-relative) may experience one or more of the following side effects.

      • Bleeding into the brain. This is the major risk of Alteplase treatment and may lead to permanent disability or death. Bleeding can occur into the stroke damaged brain as the clot is broken down but may also occur elsewhere in the brain. Bleeding into the brain with clinical deterioration occurs in less than 3% of patients treated with Alteplase. This risk of treatment has to be balanced against the potential for reducing the size of the stroke.
      • Bleeding from the gut or urinary tract. This bleeding may be difficult to control, and occasionally the loss of blood may require medical treatment including a blood transfusion.
      • Bruising or bleeding from the injection site, nose or gums. Generally, such bleeding is easily controlled.
      • An inflamed and painful injection site.
      • Other infrequent risks of Alteplase treatment include a transient rise in body temperature, lowering of blood pressure, nausea and vomiting, rash or breathing problems. Should any of these occur your doctor would be ready to treat with appropriate medication.
      • As with all new drugs, there may be other risks we do not know about.

      You can ask for any information you want

      The decision whether or not you wish to receive Alteplase is your choice. If you choose not to receive this treatment you do not have to give a reason and you will continue to receive all standard care for stroke patients. If you would like more information about Alteplase or if there is any matter about it that concerns you, either now or in the future, do not hesitate to ask one of the clinical team treating you.

    • * The following is taken from the NZ Formulary

      Alteplase is recommended in the treatment of acute ischaemic stroke if it can be administered within 4.5 hours of symptom onset; it should be given by medical staff experienced in the administration of thrombolytics and the treatment of acute stroke, preferably within a specialist stroke centre. Treatment with aspirin 300 mg once daily for 14 days should be initiated 24 hours after thrombolysis (or as soon as possible within 48 hours of symptom onset in patients not receiving thrombolysis); patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel 75 mg once daily [unapproved indication] as an alternative.

      Anticoagulants are not recommended as an alternative to antiplatelet drugs in acute ischaemic stroke in patients who are in sinus rhythm. However, parenteral anticoagulants may be indicated in patients who are symptomatic of, or at high risk of developing, deep vein thrombosis or pulmonary embolism; warfarin should not be commenced in the acute phase of ischaemic stroke.

      Anticoagulation therapy for long-term secondary prevention should be used in all people with ischaemic stroke or TIA who have atrial fibrillation or cardioembolic stroke and no contra-indication. In acute ischaemic stroke, the decision to commence anticoagulation therapy can be delayed for up to two weeks but should be made prior to discharge. Patients already receiving anticoagulation for a prosthetic heart valve who experience a disabling ischaemic stroke and are at significant risk of haemorrhagic transformation, should have their anticoagulant treatment stopped for 7 days and substituted with aspirin 300 mg once daily.

      Treatment of hypertension in the acute phase of ischaemic stroke can result in reduced cerebral perfusion, and should therefore only be instituted in the event of a hypertensive emergency or in those patients considered for thrombolysis.

    • If yes, call 111 Status 2. Admit directly to ED
    • St John's immediately dispatch ambulances to patients who are possible thrombolysis candidates with lights and sirens as per their protocol - make the status of the patient clear when requesting an ambulance and ensure they understand the urgency.
    • The ambulance crew will call ED enroute to the hospital to alert them.  The emergency dept thrombolysis in acute ischaemic stroke protocol will be followed by ED which requires the ED Doctor to alert either the Stroke Team or on-call Medical Registrar (depending on whether the patient is in Tauranga or Whakatane and depending on the time of day), to the need for an immediate assessment.
    • This is therefore one of the only times when GPs do NOT have to call the Acute Admitting Team prior to the patient's arrival. A referral letter as per the next box, would be useful, however.
  2. While awaiting ambulance

    • Having called the ambulance the following can be done:
    • Check the blood sugar of the patient.
    • Give O2 if sats <95% and no contraindication.
    • Keep NBM.
    • Have a family member accompany the patient to assist with urgent consent issues.
    • Complete referral letter paying particular attention to medications, recent trauma or surgery or any other bleeding risk which might be a contraindication to thrombolysis. (For those with Medtech there is an 'acute' eReferral that can be completed.  These are picked up immediately at ED and allows patient notes to be accessed prior to their arrival.  Send a paper copy too, with the patient).
    • Aspirin should NOT be given until a CT scan has excluded haemorrhage.
  3. Acute hospital assessment

  4. Inpatient Stroke Care

    • The Acute Stroke Unit (ASU) is a 6-bed unit opened in January 2013 in Tauranga hospital to provide optimal post stroke management and care. Patients in Whakatane receive daily multidisciplinary team assessments and consultant review to achieve the very best outcomes possible.
    • Bay of Plenty DHB Stroke Management Guidelines will be available soon
  5. Rehabilitation

    • Physiotherapy, occupational therapy, speech and language therapy, dietitian, social worker and diabetic specialist nurse (as appropriate) assessments are made on a daily basis until the patient is discharged. Prior to discharge, assessments will be made to ensure that the patient has appropriate support in the community setting. A visual assessment will also have been made to assess any field deficits.
  6. Antiplatelet Therapy

    • The current BOPDHB Stroke team preferred long-term anti-platelet therapy for those that do not require anticoagulation (i.e. warfarin or dabigatran) is:
      1. Clopidogrel 75mg od.
      2. Aspirin 100mg od and Dipyridamole 150mg bd as an alternative for those not able to tolerate Clopidogrel.
      3. Aspirin alone should only be used by those unable to tolerate Clopidogrel and Dipyridamole.
    • Clopidogrel - NZ Formulary
    • Dipyridamole - NZ Formulary
      • Long-term Management
        1. Patients should receive long-term treatment following a transient ischaemic attack or an ischaemic stroke to reduce the risk of further cardiovascular events.
        2. Low dose aspirin and modified release dipyridamole or clopidogrel alone should be prescribed to all people with ischaemic stroke or TIA taking into consideration patient comorbidities. Aspirin alone can also be used, particularly in patients who do not tolerate aspirin plus dipyridamole or clopidogrel. If both aspirin and clopidogrel are contra-indicated or not tolerated, then modified-release dipyridamole alone is recommended; if both dipyridamole and clopidogrel are contraindicated or not tolerated, then aspirin alone is recommended.
        3. Patients with stroke associated with atrial fibrillation should be reviewed for long-term treatment with warfarin or an alternative anticoagulant (see Initial Management under Ischaemic Stroke, above). 
        4. Anticoagulants are not routinely recommended in the long-term prevention of recurrent stroke, except in patients with atrial fibrillation.
        5. A statin should be initiated 48 hours after ischaemic stroke or TIA symptom onset, irrespective of the patient’s serum-cholesterol concentration.
        6. Following the acute phase of ischaemic stroke, blood pressure should be measured and treatment initiated to achieve a target blood pressure of <130/80 mmHg. Beta-blockers should not be used in the management of hypertension following a stroke, unless they are indicated for a co-existing condition.
        7. All patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight, alcohol intake, and smoking.

       

Management for Strokes >4 hours from the symptom onset

  1. Admit to Hospital via the Acute Medical Team

    • Patients suspected of having a Stroke outside of the 4 hour 'thrombolysis window' should still be admitted ASAP for an appropriate assessment and diagnosis.
    • These patients should be admitted via the Acute Medical Team on call.  Patients will be assessed according to the 
      Quick Reference Acute Stroke pathway for use by Assessing Acute Medical Team

      1. Suspected Stroke

      2. If less than 4 hours from onset of symptoms refer thrombolysis pathway

      3. For those outside of the thrombolysis window perform a Clinical Assessment

      4. Perform IMMEDIATE CT head if ANY of the following:

      • Thrombolysis candidate
      • Anticoagulated
      • Reduced or deteriorating conscious level
      • SAH
      • Suspected neurosurgical diagnosis eg SDH or brain sepsis

      5. Tests in ALL Patients:

      • 12-lead ECG
      • CBC, U&E, ESR, glucose, LFT, lipid profile
      • CT head within 24 hours (including weekends)

      6. Test in SELECTED Patients:

      • TFTs if in AF
      • INR if on warfarin
      • Carotid Dopplers in anterior circulation strokes (good recovery or low disability)
      • CXR if smoking history or cardio-respiratory disease
      • Telemetry if ?PAF
      • ECHO, thrombolysis screen, vasculitis screen are usually reserved for young 'cryptogenic' stroke patients who should be assessed by a stroke specialist

      7. Acute Treatment

      • Asprin only: 300mg/day - once CT head excludes haemorrhage (+/-PPI)
      • Ensure normal Sp02 and temperature
      • Treat hypo or hyperglycaemia
      • Do NOT prescribe thromboprophylaxis
      • Do not prescribe new statins within the first 48 hrs
      • Do not start new antihypertensives unless BP >220/120 (infract) or >180/100 (haemorrhage)
      • Do NOT prescribe anticoagulants (see full guideline for details) If any patient is already on antihypertensives and a statin, these should be continued unless the BP is low.

      8. Refer all stroke patients to the Stroke Team (HIA)

       Once a diagnosis is confirmed these patients will be referred to the HIA team/Acute Stroke Unit (Tauranga) or Medical Team/Stroke bed (Whakatane).
    • When the requirement for admission is less clear, advice is available between 8am-4pm from the stroke specialist on 027 403 3951. In the EBOP this is available from the Medical SMO on call via switchboard.
  2. Inpatient Stroke Care

    • The Acute Stroke Unit (ASU) is a 6-bed unit opened in January 2013 in Tauranga hospital to provide optimal post stroke management and care. Patients in Whakatane receive daily multidisciplinary team assessments and consultant review to achieve the very best outcomes possible. 
    • Bay of Plenty DHB Stroke Management Guidelines will be available soon
  3. Rehabilitation

    • Physiotherapy, occupational therapy, speech and language therapy, dietitian, social worker and diabetic specialist nurse (as appropriate) assessments are made on a daily basis until the patient is discharged. Prior to discharge, assessments will be made to ensure that the patient has appropriate support in the community setting. A visual assessment will also have been made to assess any field deficits.
  4. Antiplatelet Therapy

    • The current BOPDHB Stroke team preferred long-term anti-platelet therapy for those that do not require anticoagulation (i.e. warfarin or dabigatran) is:
      1. Clopidogrel 75mg od.
      2. Aspirin 100mg od and Dipyridamole 150mg bd as an alternative for those not able to tolerate Clopidogrel.
      3. Aspirin alone should only be used by those unable to tolerate Clopidogrel and Dipyridamole.
    • Clopidogrel - NZ Formulary
    • Dipyridamole - NZ Formulary
      • Long-term Management
        1. Patients should receive long-term treatment following a transient ischaemic attack or an ischaemic stroke to reduce the risk of further cardiovascular events.
        2. Low dose aspirin and modified release dipyridamole or clopidogrel alone should be prescribed to all people with ischaemic stroke or TIA taking into consideration patient comorbidities. Aspirin alone can also be used, particularly in patients who do not tolerate aspirin plus dipyridamole or clopidogrel. If both aspirin and clopidogrel are contra-indicated or not tolerated, then modified-release dipyridamole alone is recommended; if both dipyridamole and clopidogrel are contraindicated or not tolerated, then aspirin alone is recommended.
        3. Patients with stroke associated with atrial fibrillation should be reviewed for long-term treatment with warfarin or an alternative anticoagulant (see Initial Management under Ischaemic Stroke, above). 
        4. Anticoagulants are not routinely recommended in the long-term prevention of recurrent stroke, except in patients with atrial fibrillation.
        5. A statin should be initiated 48 hours after ischaemic stroke or TIA symptom onset, irrespective of the patient’s serum-cholesterol concentration.
        6. Following the acute phase of ischaemic stroke, blood pressure should be measured and treatment initiated to achieve a target blood pressure of <130/80 mmHg. Beta-blockers should not be used in the management of hypertension following a stroke, unless they are indicated for a co-existing condition.
        7. All patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight, alcohol intake, and smoking.

       

Information

  • Cerebrovascular disease

    This group of conditions includes strokes arising from occlusive vascular disease (cerebral thrombosis), spontaneous intracerebral haemorrhage and transient ischaemic attacks. People who have suffered strokes are at increased risk of a second attack that may render them unconscious or incapable of handling a motor vehicle. The residual effects of stroke in terms of hemiplegia or other neurological sequelae such as perceptual and visual problems, as well as effects on cognition, are often sufficient to render an individual unfit to drive. Transient ischaemic attacks may also render an individual unconscious or unable to control a vehicle.

    Cerebrovascular accident (CVA)

    Where there is doubt about fitness to drive in terms of residual disability in any area, a driving assessment by an occupational therapist trained to provide off-road and/or on-road assessments should be undertaken.

    Medical standards for individuals applying for or renewing a class 1 or class 6 licence and/or a D, F, R, T or W endorsement.

    When driving should cease:

    An individual should not drive until clinical recovery is complete, with no significant residual disability likely to compromise safety. However, this period should not be less than one month from the event.

    Individuals with the presence of homonymous hemianopia are generally considered permanently unfit to drive. The presence of other disorders such as ataxia, vertigo and diplopia will also generally make individuals permanently unfit to drive unless there is a full level of functional recovery.

    The presence of epilepsy-associated significant cardiovascular disorders and recurrent transient ischaemic attacks following a stroke will generally result in individuals being considered unfit to drive.

    When driving may resume or may occur:

    Driving may resume when there has been satisfactory clinical recovery, providing that there is no residual limb disability that cannot be accommodated by appropriate vehicle modifications, and there is no evidence of cerebral damage resulting in cognitive defects, reduced reaction times, perceptual difficulties and visual problems such as homonymous field defects and/or hemispatial neglect.

     Individuals are generally considered unfit to drive where there is the presence of epilepsy, associated significant cardiovascular disorders and recurrent transient ischaemic attacks following a stroke. In exceptional circumstances, the Agency may consider granting a licence after 12 months if a supporting specialist physician or neurologist's report is provided with the application. If licences are granted, the Agency may impose licence conditions for regular medical assessment of fitness to drive.

     We strongly advise that, wherever there is doubt about fitness to drive in terms of cognitive or physical defects, an occupational therapist with training in driving assessment should make a full assessment. In many cases, it may be possible to allow a return to driving after suitable vehicle modifications have been made.

    Medical standards for individuals applying for or renewing a class 2, 3, 4 or 5 licence and/or a P, V, I or O endorsement

    When driving should cease:

    Licences are generally not granted to applicants with a history of cerebrovascular accident. Individuals who have suffered from a cerebrovascular event are generally considered permanently unfit to drive unless sound reasons exist for a less stringent approach. The presence of secondary epilepsy will generally result in individuals being considered permanently unfit to drive.

    When driving may resume or may occur:

    Under some circumstances, a licence may be granted with conditions to existing holders of these classes and/or endorsement types. If there has been a full and complete recovery with no suggestion of recurrence over a period of three years, the possibility of a return to driving may be considered by the Agency (via the Chief Medical Adviser). A supporting specialist physician or neurologist's report will be required.

  • Symptoms  Action  Why 

    Stroke symptoms < 4 hours from symptom onset  

    Treat as emergency – send for ED assessment via urgent ambulance (lights and sirens)

    Potential Thrombolysis candidate  

     Stroke symptoms outside the ‘thrombolysis’ 4-hour window

    Admit immediately to hospital via acute medical team 

     Early assessment, diagnosis and management will ensure the very best outcome for the patient. Will receive CT scan within 24 hours

     Symptoms unclear but may warrant admission or assessment Hours 0800-1600

     Contact the Stroke team on the ‘stroke mobile’ on 0277065064 to discuss (available to both WBOP and EBOP) 

     

    Symptoms unclear but may warrant admission or assessment Hours 1600-0800

    Contact the acute medical registrar on call for advice

     

  • This pathway was developed in collaboration with:

    Position Name

    SMO Tauranga

    *Mohan Datta-Chaudhuri

    WBOPPHO GP

    *Nick Hanna

    Behavioural Optometrist

    Brenton Clark

    BOPDHB Whk

    Rehab staff

    Clinical Nurse Manager

    Fay Mattson

    Community Allied Health Lead

    Jane Wilson

    EBOPPHA GP

    Grahame Jelley

    GM Regional Maori Health

    Amohaere Tangitu/Lani Marama

    Medical Nurse Manager Whk

    Vivienne Robertson

    Medwise Pharmacy

    Pauline McQuiod

    Nurse Practitioner

    Tony Lawson

    Nurse Specialist

    Trish Blattmann

    Physio Team Lead

    Trish Wrigley

    Physiotherapist Whk

    Eilidh McGillivray

    Portfolio Manager

    Anna Thurnell

    Program Manager

    Caroline Davy

    Project Administrator

    Jacky Maaka

    Psychologist

    Daniela Alloro

    Radiology Manager

    Jillian Wright

    Senior Physiotherapist

    Tania Dawson

    SMO Whakatane

    Chris Hulett

    Social Work Team Lead

    Brent Gilbert-De Rios

    Social Worker

    Caron Nuttal

    Social Worker

    Margaret Wood

    Speech Language Therapist

    Natalie Oakley

    St John's Ambulance

    Jeremy Gooders

    Stroke Foundation

    Angela Drummond

    Te Koru Therapy Manager Whk

    Pip Percival

    *Pathway Lead

Disclaimer: These pathways, for the care and management of patients within Bay of Plenty, have been developed jointly by primary and secondary care clinicians. They provide guidance for General Practice teams to diagnose and manage patients suffering from a number of different conditions, and contain patient information resources. The pathways are maps of publicly-funded services accessed by referral from the community, and are strongly evidence based, but are not full clinical guidelines. As the pathways are suggested guidance only, while using them you must exercise your own clinical judgement and pertinent clinical data when treating your patient. This site is intended to be flexible and frequently updated. While every effort has been made to ensure accuracy, all information should be verified.